• comply with requirements established by the FDA, including post-marketing requirements and label restrictions; and • comply with other U.S. healthcare regulatory requirements. 36 We are exposed to risks associated with the highly concentrated market for the INTERCEPT Blood System. 37 Our research and development activities involve the controlled use of hazardous materials, including certain hazardous chemicals, radioactive materials and infectious pathogens, such as HIV and hepatitis viruses. Although we ...

Cerus Corporation (NASDAQ:CERS) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Jessica Hanover – Vice President-Corporate Affairs Obi Greenman – President and Chief Executive Officer Vivek Jayaraman – Chief Operating Officer Kevin Green – Chief Financial Officer Conference Call Participants Brandon Folkes – Cantor Fitzgerald Matt Blackman – Stifel Operator Good day, and welcome to the Cerus Corporation’s First Quarter 2023 Earnings Conference Call. At this time all participant ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Common Stock, pa ...

Cerus Corp (NASDAQ:CERS) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Joel Trujillo - Senior Director, IR William Greenman - President, CEO & Director Vivek Jayaraman - COO Kevin Green - VP, Finance & CFO Carol Moore - SVP, Regulatory Affairs, Quality & Clinical Conference Call Participants Mathew Blackman - Stifel, Nicolaus & Company Jacob Johnson - Stephens Inc. Brandon Folkes - Cantor Fitzgerald Joshua Jennings - Cowen and Company Operator Good day, ladies and gentle ...

60 See Note 7, Debt, in Part IV, Item 15, "Exhibits and Financial Statement Schedules" of this Annual Report on Form 10-K for more information on the debt under our Term Loan Credit Agreement and the Revolving Loan Credit Agreement. Critical Accounting Policies and Management Estimates Results of Operations Cost of Product Revenue Research and Development Expenses uncertainties associated with the successful completion of our research and development projects, which risks and uncertainties are discussed in ...

Cerus Corporation (NASDAQ:CERS) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Jessica Hanover - Vice President, Corporate Affairs Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Brandon Folkes - Cantor Fitzgerald Operator Good day and thank you for standing by. Welcome to the Cerus Corporation’s Quarter Three 2022 Earnings Conference C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) ...

Cerus Corporation (NASDAQ:CERS) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Matt Notarianni - Senior Director-Investor Relations Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Richard Benjamin - Chief Medical Officer Conference Call Participants Mathew Blackman - Stifel Brandon Folkes - Cantor Fitzgerald Josh Jennings - Cowen Operator Good day, ladies and gentlemen. Thank you for standin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of t ...

Cerus Corporation (NASDAQ:CERS) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Matt Notarianni – Senior Director-Investor Relations Obi Greenman – President and Chief Executive Officer Vivek Jayaraman – Chief Operating Officer Kevin Green – Chief Financial Officer Conference Call Participants Brandon Folkes – Cantor Fitzgerald Eric Anderson – Cowen Operator Good day, ladies and gentlemen. Thank you for standing by. And welcome to the Cerus Corporation First Quarter 2022 Earning ...